All In Biotech

Drug Trial Radar · NCT03068897

Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain

Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: A Randomized Trial

Last checked: Nov 19, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

320

Actual

Start

May 3, 2017

Primary completion

Jul 11, 2018

Study completion Oct 11, 2018

Sponsor

Lead sponsor
Montefiore Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized study, based in emergency departments, in which the investigators determine the utility of adding various skeletal muscle relaxants to standard therapy, which consists of ibuprofen and an educational session. Patients will be enrolled at the time of an emergency visit and followed for three months to determine outcomes.

Conditions

  • Low Back Pain

Interventions

  • MetaxaloneDrug

    Metaxalone 400-800mg

  • TizanidineDrug

    Tizanidine 2-4mg

  • BaclofenDrug

    Baclofen 10-20mg

  • Ibuprofen 600 mgDrug

    Ibuprofen

  • Educational interventionBehavioral

    Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ)Time frame: Baseline and 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Montefiore Medical Center

    The Bronx, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.